Metabolomic Approaches in Lung Cancer Diagnostics

Metabolomic approaches in lung cancer diagnostics harness the comprehensive analysis of small molecules—metabolites—within biological specimens to elucidate the unique chemical fingerprints of tumour development. By profiling metabolites in blood, saliva, tissue or pleural effusions, researchers can detect perturbations in pathways such as glycolysis, lipid synthesis, amino acid turnover and bile acid metabolism that accompany malignant transformation. High-resolution technologies—including liquid chromatography–mass spectrometry and nuclear magnetic resonance—combined with advanced statistical and machine-learning methods enable the identification of diagnostic and prognostic biomarkers. These non-invasive or minimally invasive assays promise to complement imaging and cytology by improving early detection, stratifying risk and monitoring therapeutic response. Global initiatives have underscored the value of integrating multi-site cohorts and longitudinal sampling to capture metabolic evolution from premalignant lesions to invasive disease, while methodological advances continue to refine sensitivity, reproducibility and the translation of complex signatures into clinical practice.

Research from Nature Portfolio

Recent studies have mapped the metabolic evolution of lung adenocarcinoma from atypical adenomatous hyperplasia through minimally invasive stages to fully invasive carcinoma. Large-scale targeted metabolomics of resected lesions and paired plasma revealed that key pathways—such as bile acid metabolism and glycerophospholipid remodelling—display early perturbations, enabling the derivation of non-invasive plasma panels that distinguish invasive tumours from benign nodules. Unsupervised clustering of these profiles further defined metabolic subtypes linked to clinical outcomes, with one subtype characterised by aberrant bile acid handling that promotes tumour cell migration and offers a potential therapeutic vulnerability. Another seminal work applied ultrahigh-performance liquid chromatography–mass spectrometry alongside gas chromatography–mass spectrometry to serum from early-stage non-small cell lung cancer patients. It uncovered a panel of monounsaturated and polyunsaturated phosphatidylcholines whose altered abundances in glycerophospholipid metabolism accurately discriminated cancer cases from healthy controls, suggesting a lipid signature for early-stage diagnosis.

Metabolomic Approaches in Lung Cancer Diagnostics publication trend

The graph below shows the total number of articles in metabolomic approaches in lung cancer diagnostics across all publications each year (not limited to Nature Index journals).

Technical terms

Metabolomics: Global measurement of small molecular metabolites in a biological sample to characterise metabolic states.

Lipidomics: Subset of metabolomics focusing on comprehensive profiling of lipid species and their roles in physiology and disease.

Glycerophospholipids: Major membrane lipids composed of glycerol, phosphate and fatty acid chains; often dysregulated in cancer.

Mass spectrometry: Analytical technique that ionises chemical compounds to measure their mass-to-charge ratios, enabling metabolite identification and quantification.

Biomarker: Measurable indicator of a biological state or condition, used for diagnosis, prognosis or monitoring of treatment response.

References

1. Lung cancer metabolomics: a pooled analysis in the Cancer Prevention Studies. BMC Medicine (2024).
2. Lipidomics reveals new lipid-based lung adenocarcinoma early diagnosis model. EMBO Molecular Medicine (2024).
3. Simultaneous quantification of serum monounsaturated and polyunsaturated phosphatidylcholines as potential biomarkers for diagnosing non-small cell lung cancer. Scientific Reports (2018).
4. Evolutionary metabolic landscape from preneoplasia to invasive lung adenocarcinoma. Nature Communications (2021).